Allan Jonathan, serving as General Counsel and Corporate Secretary, has demonstrated a clear selling bias in his recent insider trading activity, as reflected in SEC Form 4 filings. Over the course of 38 transactions, Jonathan has sold shares totaling $2,118,099.47, significantly outweighing his $162,200 in purchases. Notably, all 18 of his most recent trades, spanning from December 2025 to March 2026, were sales of shares in Stoke Therapeutics (STOK). These sales ranged widely in value, from smaller transactions like $2,365.20 on March 18, 2026, to substantial disposals such as $292,358.90 on March 20, 2026. The consistency and volume of these sales suggest a deliberate effort to reduce his holdings in STOK.
Jonathan’s trading activity has been concentrated exclusively in STOK, with no diversification across other companies. His sales have been executed in multiple tranches, often on the same day, indicating a systematic approach to divesting his position. For instance, on December 5, 2025, he sold shares worth $168,997.18, $74,444.74, and $31,455.72 in separate transactions. This pattern of frequent and sizable sales underscores a significant reduction in his equity stake in STOK. While the filings provide no insight into the rationale behind these transactions, the data highlights a pronounced trend toward liquidation rather than accumulation of shares in Jonathan’s portfolio.
AI-assisted summary